AbbVie Inc. Selling, General and Administrative (SG&A) Expenses Growth

Selling, General and Administrative (SG&A) Expenses Growth of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative (SG&A) Expenses Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative (SG&A) Expenses Growth for the quarter ending December 30, 2019 was 1.14% (a -108.35% decrease compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative (SG&A) Expenses Growth decreased by -118.39%
  • Annual Selling, General and Administrative (SG&A) Expenses Growth for 2019 was -6.18% (a -135.23% decrease from previous year)
  • Annual Selling, General and Administrative (SG&A) Expenses Growth for 2018 was 17.54% (a 149.15% increase from previous year)
  • Annual Selling, General and Administrative (SG&A) Expenses Growth for 2017 was 7.04% (a -188.89% decrease from previous year)
  • Twelve month Selling, General and Administrative (SG&A) Expenses Growth ending December 30, 2019 was -6.18% (a -9.25% decrease compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative (SG&A) Expenses Growth decreased by -172.11% year-over-year
Trailing Selling, General and Administrative (SG&A) Expenses Growth for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
-6.18% -6.81% 3.13% 8.57%
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative (SG&A) Expenses Growth of AbbVie Inc.

Most recent Selling, General and Administrative (SG&A) Expenses Growthof ABBV including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative (SG&A) Expenses Growth of AbbVie Inc.

AbbVie Inc. Selling, General and Administrative (SG&A) Expenses Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 1.14% -13.65% -6.02% -6.2% -6.18%
2018 -1.38% 31.71% 16.63% 30.44% 17.54%
2017 16.5% 5.5% 2.93% 1.33% 7.04%
2016 -3.34% -6.31% -13.92% -8.01% -7.92%
2015 -48.01% -7.59% 17.61% 9.93% -17.31%
2014 130.73% 26.49% 2.99% 8.33% 44.32%
2013 2.62% 16.22% 12.84% -0.8% 7.28%
2012 -70.08% -7.89% -15.35%
2011 54.29%
2010 14.08%

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.